Show simple item record

dc.contributor.authorParker, C. C. [et al]en
dc.contributor.authorSheehan, Denise Jen
dc.date.accessioned2018-11-08T12:52:52Z
dc.date.available2018-11-08T12:52:52Z
dc.date.issued2018-10-18
dc.identifier.citationRadiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. 2018 Lanceten
dc.identifier.issn1474-547X
dc.identifier.pmid30355464
dc.identifier.doi10.1016/S0140-6736(18)32486-3
dc.identifier.urihttp://hdl.handle.net/11287/620905
dc.description.abstractBased on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0140-6736(18)32486-3en
dc.rightsArchived with thanks to Lancet (London, England). This is an Open Access article under the CC BY 4.0 license.en
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleRadiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.en
dc.typeJournal Articleen
dc.identifier.journalLanceten
dc.description.noteThis article is freely available via Open Access.en
dc.type.versionIn press (epub ahead of print)en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record